Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1993 Dec;61(12):5035–5043. doi: 10.1128/iai.61.12.5035-5043.1993

Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

J P de Boer 1, A A Creasey 1, A Chang 1, J J Abbink 1, D Roem 1, A J Eerenberg 1, C E Hack 1, F B Taylor Jr 1
PMCID: PMC281280  PMID: 7693593

Abstract

Alpha-2-macroglobulin (alpha 2M) may function as a proteinase inhibitor in vivo. Levels of this protein are decreased in sepsis, but the reason these levels are low is unknown. Therefore, we analyzed the behavior of alpha 2M in a baboon model for sepsis. Upon challenge with a lethal (4 baboons) or a sublethal (10 baboons) dose of Escherichia coli, levels of inactivated alpha 2M (i alpha 2M) steadily increased, the changes being more pronounced in the animals that received the lethal dose. The rise in i alpha 2M significantly correlated with the increase of thrombin-antithrombin III, plasmin-alpha 2-antiplasmin, and, to a lesser extent, with that of elastase-alpha 1-antitrypsin complexes, raising the question of involvement of fibrinolytic, clotting, and neutrophilic proteinases in the inactivation of alpha 2M. Experiments with chromogenic substrates confirmed that thrombin, plasmin, elastase, and cathepsin G indeed had formed complexes with alpha 2M. Changes in alpha 2M similar to those observed in the animals that received E. coli occurred in baboons challenged with Staphylococcus aureus, indicating that alpha 2M formed complexes with the proteinases just mentioned in gram-positive sepsis as well. We conclude that alpha 2M in this baboon model for sepsis is inactivated by formation of complexes with proteinases, derived from activated neutrophils and from fibrinolytic and coagulation cascades. We suggest that similar mechanisms may account for the decreased alpha 2M levels in clinical sepsis.

Full text

PDF
5035

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aasen A. O., Erichsen N. S., Gallimore M. J., Amundsen E. Studies on components of the plasma kallikrein-kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res. 1980;4:1–10. [PubMed] [Google Scholar]
  2. Abbink J. J., Kamp A. M., Nieuwenhuys E. J., Nuijens J. H., Swaak A. J., Hack C. E. Predominant role of neutrophils in the inactivation of alpha 2-macroglobulin in arthritic joints. Arthritis Rheum. 1991 Sep;34(9):1139–1150. doi: 10.1002/art.1780340910. [DOI] [PubMed] [Google Scholar]
  3. Abbink J. J., Nuijens J. H., Eerenberg A. J., Huijbregts C. C., Strack van Schijndel R. J., Thijs L. G., Hack C. E. Quantification of functional and inactivated alpha 2-macroglobulin in sepsis. Thromb Haemost. 1991 Jan 23;65(1):32–39. [PubMed] [Google Scholar]
  4. Barrett A. J., Starkey P. M. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J. 1973 Aug;133(4):709–724. doi: 10.1042/bj1330709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  6. Björk I., Fish W. W. Evidence for similar conformational changes in alpha 2-macroglobulin on reaction with primary amines or proteolytic enzymes. Biochem J. 1982 Nov 1;207(2):347–356. doi: 10.1042/bj2070347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bone R. C. The pathogenesis of sepsis. Ann Intern Med. 1991 Sep 15;115(6):457–469. doi: 10.7326/0003-4819-115-6-457. [DOI] [PubMed] [Google Scholar]
  8. Colman R. W. The role of plasma proteases in septic shock. N Engl J Med. 1989 May 4;320(18):1207–1209. doi: 10.1056/NEJM198905043201809. [DOI] [PubMed] [Google Scholar]
  9. Creasey A. A., Stevens P., Kenney J., Allison A. C., Warren K., Catlett R., Hinshaw L., Taylor F. B., Jr Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock. 1991 Feb;33(2):84–91. [PubMed] [Google Scholar]
  10. Dinarello C. A. The proinflammatory cytokines interleukin-1 and tumor necrosis factor and treatment of the septic shock syndrome. J Infect Dis. 1991 Jun;163(6):1177–1184. doi: 10.1093/infdis/163.6.1177. [DOI] [PubMed] [Google Scholar]
  11. Downing M. R., Bloom J. W., Mann K. G. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry. 1978 Jun 27;17(13):2649–2653. doi: 10.1021/bi00606a030. [DOI] [PubMed] [Google Scholar]
  12. Duswald K. H., Jochum M., Schramm W., Fritz H. Released granulocytic elastase: an indicator of pathobiochemical alterations in septicemia after abdominal surgery. Surgery. 1985 Nov;98(5):892–899. [PubMed] [Google Scholar]
  13. Egbring R., Schmidt W., Fuchs G., Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood. 1977 Feb;49(2):219–231. [PubMed] [Google Scholar]
  14. Ellis V., Scully M., MacGregor I., Kakkar V. Inhibition of human factor Xa by various plasma protease inhibitors. Biochim Biophys Acta. 1982 Feb 4;701(1):24–31. [PubMed] [Google Scholar]
  15. Feinman R. D. Current perspective on the thiolester bond in alpha 2-macroglobulin. Ann N Y Acad Sci. 1983;421:472–476. doi: 10.1111/j.1749-6632.1983.tb18140.x. [DOI] [PubMed] [Google Scholar]
  16. Glauser M. P., Zanetti G., Baumgartner J. D., Cohen J. Septic shock: pathogenesis. Lancet. 1991 Sep 21;338(8769):732–736. doi: 10.1016/0140-6736(91)91452-z. [DOI] [PubMed] [Google Scholar]
  17. Gonias S. L., Pizzo S. V. Conformation and protease binding activity of binary and ternary human alpha 2-macroglobulin-protease complexes. J Biol Chem. 1983 Dec 10;258(23):14682–14685. [PubMed] [Google Scholar]
  18. Gonias S. L., Reynolds J. A., Pizzo S. V. Physical properties of human alpha 2-macroglobulin following reaction with methylamine and trypsin. Biochim Biophys Acta. 1982 Aug 10;705(3):306–314. doi: 10.1016/0167-4838(82)90252-7. [DOI] [PubMed] [Google Scholar]
  19. Harpel P. C. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest. 1981 Jul;68(1):46–55. doi: 10.1172/JCI110253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Harpel P. C., Hayes M. B. Immunoimmobilization of alpha 2-macroglobulin--beta-trypsin complexes: a novel approach for the biochemical characterization of modulator--protease interactions. Anal Biochem. 1980 Oct;108(1):166–175. doi: 10.1016/0003-2697(80)90708-3. [DOI] [PubMed] [Google Scholar]
  21. Harpel P. C. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med. 1970 Aug 1;132(2):329–352. doi: 10.1084/jem.132.2.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harpel P. C., Lewin M. F., Kaplan A. P. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. J Biol Chem. 1985 Apr 10;260(7):4257–4263. [PubMed] [Google Scholar]
  23. Harpel P. C. Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin. J Exp Med. 1977 Oct 1;146(4):1033–1040. doi: 10.1084/jem.146.4.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Harpel P. C. Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure. J Exp Med. 1973 Sep 1;138(3):508–521. doi: 10.1084/jem.138.3.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Heeb M. J., Gruber A., Griffin J. H. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha 2-macroglobulin and alpha 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem. 1991 Sep 15;266(26):17606–17612. [PubMed] [Google Scholar]
  26. Hesselvik J. F., Blombäck M., Brodin B., Maller R. Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome. Crit Care Med. 1989 Aug;17(8):724–733. doi: 10.1097/00003246-198908000-00002. [DOI] [PubMed] [Google Scholar]
  27. Hinshaw L. B., Brackett D. J., Archer L. T., Beller B. K., Wilson M. F. Detection of the 'hyperdynamic state' of sepsis in the baboon during lethal E. coli infusion. J Trauma. 1983 May;23(5):361–365. doi: 10.1097/00005373-198305000-00001. [DOI] [PubMed] [Google Scholar]
  28. Holmberg L., Lecander I., Astedt B. Binding of urokinase to plasma proteinase inhibitors. Scand J Clin Lab Invest. 1980;40(8):743–747. doi: 10.3109/00365518009095590. [DOI] [PubMed] [Google Scholar]
  29. Hoogendoorn H., Toh C. H., Nesheim M. E., Giles A. R. Alpha 2-macroglobulin binds and inhibits activated protein C. Blood. 1991 Nov 1;78(9):2283–2290. [PubMed] [Google Scholar]
  30. Imber M. J., Pizzo S. V. Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin. J Biol Chem. 1981 Aug 10;256(15):8134–8139. [PubMed] [Google Scholar]
  31. Kalter E. S., Daha M. R., ten Cate J. W., Verhoef J., Bouma B. N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis. 1985 Jun;151(6):1019–1027. doi: 10.1093/infdis/151.6.1019. [DOI] [PubMed] [Google Scholar]
  32. Kaufman N., Page J. D., Pixley R. A., Schein R., Schmaier A. H., Colman R. W. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood. 1991 Jun 15;77(12):2660–2667. [PubMed] [Google Scholar]
  33. Korninger C., Collen D. Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemost. 1981 Oct;46(3):662–665. [PubMed] [Google Scholar]
  34. Kurecki T., Kress L. F., Laskowski M., Sr Purification of human plasma alpha 2 macroglobulin and alpha 1 proteinase inhibitor using zinc chelate chromatography. Anal Biochem. 1979 Nov 1;99(2):415–420. doi: 10.1016/s0003-2697(79)80026-3. [DOI] [PubMed] [Google Scholar]
  35. Levi M., Roem D., Kamp A. M., de Boer J. P., Hack C. E., ten Cate J. W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost. 1993 Feb 1;69(2):141–146. [PubMed] [Google Scholar]
  36. Levi M., de Boer J. P., Roem D., ten Cate J. W., Hack C. E. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost. 1992 Jan 23;67(1):111–116. [PubMed] [Google Scholar]
  37. MEHL J. W., O'CONNELL W., DEGROOT J. MACROGLOBULIN FROM HUMAN PLASMA WHICH FORMS AN ENZYMATICALLY ACTIVE COMPOUND WITH TRYPSIN. Science. 1964 Aug 21;145(3634):821–822. doi: 10.1126/science.145.3634.821. [DOI] [PubMed] [Google Scholar]
  38. Maeda H., Molla A., Oda T., Katsuki T. Internalization of serratial protease into cells as an enzyme-inhibitor complex with alpha 2-macroglobulin and regeneration of protease activity and cytotoxicity. J Biol Chem. 1987 Aug 15;262(23):10946–10950. [PubMed] [Google Scholar]
  39. Martínez-Brotóns F., Oncins J. R., Mestres J., Amargós V., Reynaldo C. Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock--comparison with cardiogenic shock. Thromb Haemost. 1987 Aug 4;58(2):709–713. [PubMed] [Google Scholar]
  40. Nuijens J. H., Abbink J. J., Wachtfogel Y. T., Colman R. W., Eerenberg A. J., Dors D., Kamp A. J., Strack van Schijndel R. J., Thijs L. G., Hack C. E. Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med. 1992 Feb;119(2):159–168. [PubMed] [Google Scholar]
  41. Nuijens J. H., Huijbregts C. C., Cohen M., Navis G. O., de Vries A., Eerenberg A. J., Bakker J. C., Hack C. E. Detection of activation of the contact system of coagulation in vitro and in vivo: quantitation of activated Hageman factor-C-1-inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays. Thromb Haemost. 1987 Aug 4;58(2):778–785. [PubMed] [Google Scholar]
  42. Ohlsson K. Elimination of 125-I-trypsin alpha-macroglobulin complexes from blood by reticuloendothelial cells in dogs. Acta Physiol Scand. 1971 Feb;81(2):269–272. doi: 10.1111/j.1748-1716.1971.tb04900.x. [DOI] [PubMed] [Google Scholar]
  43. Ohlsson K., Laurell C. B. The disappearance of enzyme-inhibitor complexes from the circulation of man. Clin Sci Mol Med. 1976 Jul;51(1):87–92. doi: 10.1042/cs0510087. [DOI] [PubMed] [Google Scholar]
  44. Pixley R. A., DeLa Cadena R. A., Page J. D., Kaufman N., Wyshock E. G., Colman R. W., Chang A., Taylor F. B., Jr Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol. 1992 Apr;140(4):897–906. [PMC free article] [PubMed] [Google Scholar]
  45. Reddy V. Y., Pizzo S. V., Weiss S. J. Functional inactivation and structural disruption of human alpha 2-macroglobulin by neutrophils and eosinophils. J Biol Chem. 1989 Aug 15;264(23):13801–13809. [PubMed] [Google Scholar]
  46. Salvesen G. S., Barrett A. J. Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. Biochem J. 1980 Jun 1;187(3):695–701. doi: 10.1042/bj1870695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Schapira M., Scott C. F., Colman R. W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982 Feb;69(2):462–468. doi: 10.1172/JCI110470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Seitz R., Wolf M., Egbring R., Radtke K. P., Liesenfeld A., Pittner P., Havemann K. Participation and interactions of neutrophil elastase in haemostatic disorders of patients with severe infections. Eur J Haematol. 1987 Mar;38(3):231–240. doi: 10.1111/j.1600-0609.1987.tb01169.x. [DOI] [PubMed] [Google Scholar]
  49. Sottrup-Jensen L., Hansen H. F. Nascent alpha 2-macroglobulin-trypsin complex: incorporation of amines and water at the thiol esterified Glx-residues of alpha 2-macroglobulin during activation with trypsin. Biochem Biophys Res Commun. 1982 Jul 16;107(1):93–100. doi: 10.1016/0006-291x(82)91674-6. [DOI] [PubMed] [Google Scholar]
  50. Sottrup-Jensen L., Petersen T. E., Magnusson S. A thiol-ester in alpha 2-macroglobulin cleaved during proteinase complex formation. FEBS Lett. 1980 Dec 1;121(2):275–279. doi: 10.1016/0014-5793(80)80361-9. [DOI] [PubMed] [Google Scholar]
  51. Suffredini A. F., Harpel P. C., Parrillo J. E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989 May 4;320(18):1165–1172. doi: 10.1056/NEJM198905043201802. [DOI] [PubMed] [Google Scholar]
  52. Taylor F. B., Jr, Chang A., Esmon C. T., D'Angelo A., Vigano-D'Angelo S., Blick K. E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 1987 Mar;79(3):918–925. doi: 10.1172/JCI112902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Taylor F. B., Jr, Emerson T. E., Jr, Jordan R., Chang A. K., Blick K. E. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock. 1988 Nov;26(3):227–235. [PubMed] [Google Scholar]
  54. Taylor F. B., Jr, Hoogendoorn H., Chang A. C., Peer G., Nesheim M. E., Catlett R., Stump D. C., Giles A. R. Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C. Blood. 1992 Apr 1;79(7):1720–1728. [PubMed] [Google Scholar]
  55. Virca G. D., Travis J. Kinetics of association of human proteinases with human alpha 2-macroglobulin. J Biol Chem. 1984 Jul 25;259(14):8870–8874. [PubMed] [Google Scholar]
  56. Wakabayashi G., Gelfand J. A., Jung W. K., Connolly R. J., Burke J. F., Dinarello C. A. Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest. 1991 Jun;87(6):1925–1935. doi: 10.1172/JCI115218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. de Boer J. P., Creasey A. A., Chang A., Roem D., Eerenberg A. J., Hack C. E., Taylor F. B., Jr Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun. 1993 Oct;61(10):4293–4301. doi: 10.1128/iai.61.10.4293-4301.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. de Boer J. P., Creasy A. A., Chang A., Roem D., Brouwer M. C., Eerenberg A. J., Hack C. E., Taylor F. B., Jr Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli. Circ Shock. 1993 Jan;39(1):59–67. [PubMed] [Google Scholar]
  59. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 Dec 15;76(12):2520–2526. [PubMed] [Google Scholar]
  60. van der Graaf F., Koedam J. A., Bouma B. N. Inactivation of kallikrein in human plasma. J Clin Invest. 1983 Jan;71(1):149–158. doi: 10.1172/JCI110743. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES